Teva Pharmaceuticals USA, Inc. v. Perrigo, LLC

CourtDistrict Court, S.D. New York
DecidedFebruary 2, 2024
Docket1:23-cv-01825
StatusUnknown

This text of Teva Pharmaceuticals USA, Inc. v. Perrigo, LLC (Teva Pharmaceuticals USA, Inc. v. Perrigo, LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Teva Pharmaceuticals USA, Inc. v. Perrigo, LLC, (S.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK --- --------------------------------------------------------- X : TEVA PHARMACEUTICALS USA, INC., : Plaintiff, : : 23 Civ. 1825 (LGS) -against- : : OPINION AND ORDER PERRIGO, LLC and PERRIGO PHARMA : INTERNATIONAL D.A.C., : Defendants. : ------------------------------------------------------------ X LORNA G. SCHOFIELD, District Judge: Plaintiff Teva Pharmaceuticals USA, Inc. filed the Second Amended Complaint (the “SAC”) on May 2, 2023. The SAC asserts claims for breach of contract, unjust enrichment and promissory estoppel against Defendants Perrigo, LLC and Perrigo Pharma International D.A.C.1 Pursuant to Federal Rule of Civil Procedure 12(b)(6), Defendants move to dismiss Counts I, III, IV, V and VI in their entirety, and Count II in part. For the reasons below, the motion is granted in part and denied in part. BACKGROUND The following facts are taken from the SAC, documents incorporated by reference in it, exhibits thereto and documents of which the Court may take judicial notice. See Bellin v. Zucker, 6 F.4th 463, 473 (2d Cir. 2021).2 They are assumed to be true for purposes of this motion. See United States ex rel. Foreman v. AECOM, 19 F.4th 85, 104 (2d Cir. 2021).

1 On or about March 20, 2020, Defendant Perrigo, LLC assigned all of its rights and obligations under the Agreement to Defendant Perrigo Pharma International D.A.C. For simplicity, this opinion uses “Defendants” to refer to either or both entities, before or after that date. 2 Unless otherwise indicated, in quoting cases, all internal quotation marks, alterations, emphases, footnotes and citations are omitted. On or about June 24, 2010, Defendants, Plaintiff and Plaintiff’s affiliate executed a Binding Term Sheet (the “Agreement”). The Agreement provided for Plaintiff to manufacture and sell pharmaceutical products to Defendants in bulk and for Defendants to package the bulk product for sale in the United States. The Agreement states that Defendants would purchase

products at a price equal to Plaintiff’s Fully Absorbed Costs (“Costs”), plus five percent (the “Transfer Price”). The Agreement defines Costs as the “actual direct material costs and labor costs . . . incurred by either [party] . . . as determined in accordance with U.S. GAAP.” Plaintiff manufactured and sold Fexofenadine HCl (“Fexo”) to Defendants under the Agreement until 2021. Between 2014 and 2016, Plaintiff’s actual Costs were less than the estimated Transfer Prices invoiced to and paid by Defendants. In March 2015, the parties began negotiations for a year-end true-up. In October 2015, an agent for Defendants requested estimated costs for true- up purposes and Defendants’ budgeting, and stated that Defendants would “make true[-]ups if needed.” (emphasis omitted). In May 2017, Plaintiff reimbursed Defendants $1.04 million.

From 2017 to 2018, Plaintiff’s Costs exceeded the Transfer Prices invoiced to and paid by Defendants. Defendants refuse to satisfy Plaintiff’s requests for true-up compensation for that disparity. On or about June 1, 2021, Defendants unilaterally terminated the Agreement, cancelled all remaining purchase orders and refused to purchase the minimum quantity allegedly required by the Agreement for the remainder of 2021. LEGAL STANDARD A. Motion to Dismiss On a motion to dismiss, a court accepts as true all well-pleaded factual allegations and draws all reasonable inferences in favor of the non-moving party but does not consider conclusory allegations or legal conclusions couched as factual allegations. See Herrera v. Comme des Garcons, Ltd., 84 F.4th 110, 113 (2d Cir. 2023). To withstand a motion to dismiss, “a complaint must contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face.” Kaplan v. Lebanese Canadian Bank, SAL, 999 F.3d 842, 854 (2d Cir.

2021) (quoting Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009)). “Threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice.” Iqbal, 556 U.S. at 678; accord Dane v. UnitedHealthcare Ins. Co., 974 F.3d 183, 189 (2d Cir. 2020). It is not enough for a complaint to allege facts that are consistent with liability; it must “nudge[]” claims “across the line from conceivable to plausible.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007); accord Bensch v. Estate of Umar, 2 F.4th 70, 80 (2d Cir. 2021). To survive dismissal, “plaintiffs must provide the grounds upon which their claim rests through factual allegations sufficient to raise a right to relief above the speculative level.” Rich v. Fox News Network, LLC, 939 F.3d 112, 121 (2d Cir. 2019). B. Applicable Law

A federal court sitting in diversity applies the choice-of-law rules of the state in which it sits. Liberty Synergistics Inc. v. Microflo Ltd., 718 F.3d 138, 151-52 (2d Cir. 2013); accord Clayton Servs. LLC v. Sun W. Mortg. Co., Inc., No. 22 Civ. 511, 2023 WL 2781294, at *4 (2d Cir. Apr. 5, 2023) (summary order). New York law governs this dispute because the Agreement includes a New York choice of law provision, and the parties’ submissions assume that New York law applies. See In re Snyder, 939 F.3d 92, 100 n.2 (2d Cir. 2019) (“[I]mplied consent is . . . sufficient to establish the applicable choice of law. . . .”). DISCUSSION A. Breach of Contract for Failure to True-Up (Count I) Count I of the SAC alleges that Defendants breached the Agreement by failing to fulfill their obligation to make true-up payments for the period of 2017 to 2019. Specifically,

Defendants failed to compensate Plaintiff for the difference between Defendants’ payments based on initial estimated pricing, and the actual agreed-upon Transfer Price based on Plaintiff’s Costs, allegedly in violation of the parties’ agreement. Defendants’ motion to dismiss Count I of the SAC is denied because the SAC pleads facts sufficient to show that the parties, through their course of dealing, modified their agreement to include true-up payments, despite the restriction on modifications in their written contract. 1. Waiver and Modification New York’s Uniform Commercial Code (“UCC”) provides the governing law because the Agreement involves a “transaction in goods.” See N.Y. U.C.C. §§ 2-102 (Article 2 of the UCC applies to “transactions in goods”); 2-105(1) (“goods” includes “all things . . . which are

movable.”); accord Jet Experts, LLC v. Asian Pac. Aviation Ltd., 602 F. Supp. 3d 636, 640 (S.D.N.Y. 2022) (concluding that New York’s UCC governs because the agreement involves a “transaction in goods,” which includes all things “which are movable”). Common law principles supplement the UCC to the extent not inconsistent with its terms. N.Y. U.C.C. § 1-103(3)(b); see Antifun Ltd. T/A Premium Vape v. Wayne Indus. LLC, 616 F. Supp. 3d 291, 302 (S.D.N.Y. 2022) (New York law).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Liberty Synergistics Inc. v. Microflo Ltd.
718 F.3d 138 (Second Circuit, 2013)
PC Com, Inc. v. Proteon, Inc.
946 F. Supp. 1125 (S.D. New York, 1996)
CT Chemicals (U.S.A.) Inc. v. Vinmar Impex, Inc.
613 N.E.2d 159 (New York Court of Appeals, 1993)
Kamco Supply Corp. v. On the Right Track, LLC
2017 NY Slip Op 2025 (Appellate Division of the Supreme Court of New York, 2017)
Rich v. Fox News Network, LLC
939 F.3d 112 (Second Circuit, 2019)
Dane v. UnitedHealthcare Ins. Co.
974 F.3d 183 (Second Circuit, 2020)
Kaplan v. Lebanese Canadian Bank
999 F.3d 842 (Second Circuit, 2021)
Bensch v. Estate of Umar
2 F.4th 70 (Second Circuit, 2021)
Bellin v. Zucker
6 F.4th 463 (Second Circuit, 2021)
Slatt v. Slatt
477 N.E.2d 1099 (New York Court of Appeals, 1985)
Sunbeam Corp. v. Morris Distributing Co.
55 A.D.2d 722 (Appellate Division of the Supreme Court of New York, 1976)
JN Contemporary Art LLC v. Phillips Auctioneers LLC
29 F.4th 118 (Second Circuit, 2022)
Sewell v. Bernardin
795 F.3d 337 (Second Circuit, 2015)
Abbott v. Comme Des Garcons, Ltd.
84 F.4th 110 (Second Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
Teva Pharmaceuticals USA, Inc. v. Perrigo, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/teva-pharmaceuticals-usa-inc-v-perrigo-llc-nysd-2024.